U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982521) titled 'Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer' on May 08.
Brief Summary: This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
PIK3CA Mutation
HER2- Negative Breast Cancer
Hormone Receptor Positive Tumor
Br...